SanegeneBio, a clinically advanced biotechnology company developing innovative RNAi therapeutics, has entered into a global licensing agreement with Genentech, a member of the Roche Group.[1][2] Under the agreement, SanegeneBio granted Genentech exclusive worldwide rights to develop and commercialize one of its RNAi programs based on a proprietary RNAi platform.[1][2] SanegeneBio is responsible for early development activities, while Genentech will undertake downstream clinical development and global commercialization.[1][2] SanegeneBio will receive a $200 million priority payment and is eligible for development and commercialization milestone payments totaling up to $1.5 billion, plus tiered royalties on sales of potential products.[1][2] SanegeneBio's proprietary RNAi platform includes novel chemicals and delivery technologies for the development of siRNA drugs for multiple disease areas.[1][2] The contract was announced on February 2, 2026.[1][2]